Liposomes containing recombinant gp85 protein vaccine against ALV-J in chickens

Recombinant Marek’s Disease Virus as a Vector-Based Vaccine against Avian Leukosis Virus Subgroup J in Chicken

“…Cells were observed with a fluorescence microscope (Life, Carlsbad, CA, USA). Western blotting was performed as described previously [7], with gp85-specific mouse monoclonal antibody, p27-specific mouse monoclonal antibody [21], and mouse monoclonal anti-actin antibody (Sigma) as primary antibodies. IRDye 800CW goat anti-mouse IgG (H + L) (LiCor BioSciences, Bad Homburg, Germany) was used as the secondary antibody.…”

“…In order to control and prevent ALV-J epidemics and to protect the local chicken species in China, control methods and measures should be utilized to reduce the rate of ALV-J infection. Vaccine-based prevention is an effective control method [7,8,9]. However, there is currently no effective vaccine to prevent ALV-J infection.…”

“…However, the research showed that the inactivated vaccine cannot produce enough antibodies to protect against ALV-J infection, and the attenuated vaccine poses high risk for reactivation and infection [8]. A number of studies have suggested that a subunit vaccine containing gp85 protein plus CpG-oligodeoxynucleotides (ODN) adjuvant can induce breeder hens not only to produce higher amounts of serum antibody against ALV-J, but also to produce protective maternal antibody in hatched chickens’ sera [7,8,9]. Therefore, the genetic engineering vaccine could be a good choice for the prevention of ALV-J infection.…”

Liposomes containing recombinant E protein vaccine against duck Tembusu virus in ducks

“…Liposome is a novel immunologic adjuvant used in subunit vaccines [40] based on its many advantages: the surface coated with polyethylene glycol (PEG) can increase stability for oral delivery of insulin [41]; prepared easily; and can evoke higher and longer lasting immune response than the conversional vaccines [42,43]. Beyond that, in many experiments, protection of animal models was usually achieved by immunizing with the relevant liposome-entrapped antigens [16].…”

Antibody responses induced by recombinant ALV-A gp85 protein vaccine combining with CpG-ODN adjuvant in breeder hens and the protection for their offspring against early infection

“…Li et al reported that the inactivated vaccine against ALV-B could induce high titer antibody reaction and it could provide maternal antibodies to protect chickens against early infection (Li et al, 2013b), Recently we also reported that the subunit vaccine containing ALV-J gp85 protein combining with CpG-ODN adjuvant can induce breeding hens to produce http://dx.doi.org/10.1016/j.antiviral.2015.01.007 0166-3542/Ó 2015 Elsevier B.V. All rights reserved. maternal antibody and protection for hatched chickens against ALV-J early infection (Dou et al, 2013;Zhang et al, 2014), but there are no reports on ALV-A vaccines till now. In this study, the subunit vaccine containing gp85 protein of ALV-A was prepared using Escherichia coli and combining CpG-ODNs adjuvant was inoculated into breeding hens for 3 times, and the results indicated that the gp85 protein plus CpG-ODN adjuvant could produce better antibody responses than single gp85 protein and protect 80% of the offspring chickens against ALV-A early infection.…”